



Clinical trial results:

A Phase 4, Open-Label, Single-Arm Trial to Describe the Safety, Tolerability, And Immunogenicity of Trumenba® When Administered to Immunocompromised Participants 10 Years of Age

Summary

EudraCT number	2018-002588-24
Trial protocol	CZ PL
Global end of trial date	06 September 2023

Results information

Result version number	v1 (current)
This version publication date	17 March 2024
First version publication date	17 March 2024

Trial information

Trial identification

Sponsor protocol code	B1971060
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04893811
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235E 42nd Street, New York, United States, NY 10017
Public contact	PfizerClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	PfizerClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 November 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 September 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main immunogenicity objective of the study was to describe the immune response induced by 2 doses of Trumenba in immunocompromised subjects and historical age-matched healthy subjects as measured by serum bactericidal assay using human complement (hSBA) performed with 4 primary *Neisseria meningitidis* serogroup B (MnB) test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein. The main safety objective of the study was to evaluate the safety profile of Trumenba in immunocompromised subjects and historical age-matched healthy subjects.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 August 2021
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Czechia: 16
Country: Number of subjects enrolled	Finland: 5
Country: Number of subjects enrolled	Poland: 17
Country: Number of subjects enrolled	Türkiye: 24
Country: Number of subjects enrolled	United States: 42
Worldwide total number of subjects	104
EEA total number of subjects	38

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	4
Adolescents (12-17 years)	14
Adults (18-64 years)	83
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 53 subjects were enrolled at multiple sites. Study started from 18 August 2021 and completed on 06 September 2023.

Pre-assignment

Screening details:

Age- and sex-matched healthy subjects from groups 2 or 4 (Trumenba) of previously completed Phase 3 study B1971057 Stage 1 were used as control arm in this study; their historical data was used as reference for safety and immunogenicity analysis.

Period 1

Period 1 title	Vaccination phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Trumenba

Arm description:

Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 millilitre (mL), intramuscularly (IM) on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).

Arm type	Experimental
Investigational medicinal product name	Trumenba
Investigational medicinal product code	PF-05212366
Other name	Bivalent rLP2086 and meningococcal serogroup B vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 mL, IM on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).

Arm title	Trumenba: From B1971057, Control Arm
------------------	--------------------------------------

Arm description:

Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1 (NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.

Arm type	Active comparator
Investigational medicinal product name	Trumenba
Investigational medicinal product code	PF-05212366
Other name	Bivalent rLP2086 and meningococcal serogroup B vaccine
Pharmaceutical forms	Powder and solvent for suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 0.5 mL IM injection at Month 0 (first dose along with Menveo) and at Month 6 (second dose, single) during Stage 1 of the study B1971057.

Investigational medicinal product name	Meningococcal group A, C, W-135, and Y conjugate vaccine (MenACWY-CRM)
Investigational medicinal product code	
Other name	Menveo

Pharmaceutical forms	Concentrate and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 0.5 mL IM injection at Month 0 (first dose along with Trumenba) during Stage 1 of the study B1971057.

Number of subjects in period 1	Trumenba	Trumenba: From B1971057, Control Arm
Started	53	51
Vaccination 1	53	51
Vaccination 2	47	47
Completed	47	47
Not completed	6	4
Consent withdrawn by subject	2	1
No longer meets eligibility criteria	-	1
Death	1	-
Unspecified	-	1
Lost to follow-up	1	1
Protocol deviation	2	-

Period 2

Period 2 title	Follow-up phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Trumenba

Arm description:

Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 mL, IM on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).

Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Trumenba: From B1971057, Control Arm

Arm description:

Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1 (NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2	Trumenba	Trumenba: From B1971057, Control Arm
Started	47	47
Completed	47	46
Not completed	0	1
Lost to follow-up	-	1

Baseline characteristics

Reporting groups

Reporting group title	Trumenba
Reporting group description: Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 millilitre (mL), intramuscularly (IM) on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).	
Reporting group title	Trumenba: From B1971057, Control Arm
Reporting group description: Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1(NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.	

Reporting group values	Trumenba	Trumenba: From B1971057, Control Arm	Total
Number of subjects	53	51	104
Age Categorical Units: Subjects			
Children (2-11 years)	2	2	4
Adolescents (12-17 years)	8	6	14
Adults (18-64 years)	40	43	83
From 65-84 years	3	0	3
Age Continuous Units: years			
arithmetic mean	32.5	22.2	
standard deviation	± 16.55	± 4.26	-
Gender Categorical Units: Subjects			
Female	23	21	44
Male	30	30	60
Race Units: Subjects			
White	53	46	99
Black or African American	0	3	3
Asian	0	2	2
Ethnicity Units: Subjects			
Hispanic/Latino	0	7	7
Not Hispanic/Latino	53	44	97

End points

End points reporting groups

Reporting group title	Trumenba
Reporting group description: Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 millilitre (mL), intramuscularly (IM) on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).	
Reporting group title	Trumenba: From B1971057, Control Arm
Reporting group description: Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1 (NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.	
Reporting group title	Trumenba
Reporting group description: Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 mL, IM on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).	
Reporting group title	Trumenba: From B1971057, Control Arm
Reporting group description: Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1 (NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.	
Subject analysis set title	Trumenba: From B1971057, Control Arm
Subject analysis set type	Per protocol
Subject analysis set description: Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1 (NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.	

Primary: Percentage of Subjects With Serum Bactericidal Assay Using Human Complement (hSBA) Titer \Rightarrow Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline

End point title	Percentage of Subjects With Serum Bactericidal Assay Using Human Complement (hSBA) Titer \Rightarrow Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline ^{[1][2]}
End point description: The percentage of subjects who achieved an hSBA titer (A22) $\Rightarrow 1:16$, and hSBA titer (A56, B24, and B44) $\Rightarrow 1:8$ are reported. Evaluable immunogenicity set included all subjects who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before vaccination 1) and 1 month after Vaccination 2 (28-42 Days after Visit 3), had at least 1 valid and determinate assay result 1 Month after Vaccination 2, received no prohibited vaccines or medications through visit 4, and had no major protocol deviations through visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given immunogenicity set. Here, "n" signifies number of subjects evaluable for specified rows.	
End point type	Primary
End point timeframe: Baseline (Before Vaccination 1)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned for this endpoint. [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Subject analysis set has been created to report data for control arm.	

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	43	44		
Units: Percentage of subjects				
number (confidence interval 95%)				
PMB80 (A22) (n =43, 42)	32.6 (19.1 to 48.5)	31.0 (17.6 to 47.1)		
PMB2001 (A56) (n =43, 43)	25.6 (13.5 to 41.2)	23.3 (11.8 to 38.6)		
PMB2948 (B24) (n =42, 43)	2.4 (0.1 to 12.6)	23.3 (11.8 to 38.6)		
PMB2707 (B44) (n =43, 44)	9.3 (2.6 to 22.1)	11.4 (3.8 to 24.6)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2

End point title	Percentage of Subjects With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2 ^[3] ^[4]
-----------------	--

End point description:

The percentage of subjects who achieved an hSBA titer (A22) =>1:16, and hSBA titer (A56, B24, and B44) =>1:8 are reported. Evaluable immunogenicity set included all subjects who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before Vaccination 1) and 1 month after Vaccination 2 (28-42 days after Visit 3), had at least 1 valid and determinate assay result 1 month after Vaccination 2, received no prohibited vaccines or medications through Visit 4, and had no major protocol deviations through Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given immunogenicity set. Here, "n" signifies number of subjects evaluable for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

1 Month after Vaccination 2

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	44	44		
Units: Percentage of subjects				
number (confidence interval 95%)				

PMB80 (A22) (n =44, 43)	75.0 (59.7 to 86.8)	95.3 (84.2 to 99.4)		
PMB2001 (A56) (n =44, 44)	90.9 (78.3 to 97.5)	100.0 (92.0 to 100.0)		
PMB2948 (B24) (n =44, 44)	70.5 (54.8 to 83.2)	81.8 (67.3 to 91.8)		
PMB2707 (B44) (n =43, 42)	79.1 (64.0 to 90.0)	92.9 (80.5 to 98.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Local Reactions Within 7 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Local Reactions Within 7 Days After Vaccination 1 ^[5] ^[6]
-----------------	--

End point description:

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling were graded as mild (>2.0 to 5.0cm), moderate (>5.0 to 10.0cm) and severe (>10.0cm). Pain at injection site graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Vaccination 1 safety set = all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" = number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 1

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)				
Redness: Any	18.9 (9.4 to 32.0)	11.8 (4.4 to 23.9)		
Redness: Mild	5.7 (1.2 to 15.7)	5.9 (1.2 to 16.2)		
Redness: Moderate	9.4 (3.1 to 20.7)	3.9 (0.5 to 13.5)		
Redness: Severe	3.8 (0.5 to 13.0)	2.0 (0.0 to 10.4)		
Swelling: Any	22.6 (12.3 to 36.2)	11.8 (4.4 to 23.9)		

Swelling: Mild	7.5 (2.1 to 18.2)	7.8 (2.2 to 18.9)		
Swelling: Moderate	15.1 (6.7 to 27.6)	3.9 (0.5 to 13.5)		
Swelling: Severe	0 (0.0 to 6.7)	0 (0.0 to 7.0)		
Pain at injection site: Any	86.8 (74.7 to 94.5)	80.4 (66.9 to 90.2)		
Pain at injection site: Mild	41.5 (28.1 to 55.9)	47.1 (32.9 to 61.5)		
Pain at injection site: Moderate	32.1 (19.9 to 46.3)	33.3 (20.8 to 47.9)		
Pain at injection site: Severe	13.2 (5.5 to 25.3)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Local Reactions Within 7 Days After Vaccination 2

End point title	Percentage of Subjects Reporting Local Reactions Within 7 Days After Vaccination 2 ^[7] ^[8]
-----------------	--

End point description:

Local reactions (redness, swelling, and pain) at the site of investigational product administration recorded in e-diary. Redness and swelling measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling graded as mild (>2.0-5.0cm), moderate (>5.0-10.0cm) and severe (>10.0cm). Pain at injection site graded as mild (didn't interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Vaccination 2 safety set = all subjects who received the second dose of study intervention at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. "Number of Subjects Analyzed": subjects present in the given safety set. All subjects in given safety set are not contributing to data for each specified rows but were evaluable for this endpoint. "n": subjects analysed for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 2

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)				
Redness: Any (n =45, 43)	20.0 (9.6 to 34.6)	7.0 (1.5 to 19.1)		
Redness: Mild (n =45, 43)	6.7 (1.4 to 18.3)	2.3 (0.1 to 12.3)		

Redness: Moderate (n =45, 43)	11.1 (3.7 to 24.1)	4.7 (0.6 to 15.8)		
Redness: Severe (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Swelling: Any (n =45, 43)	26.7 (14.6 to 41.9)	4.7 (0.6 to 15.8)		
Swelling: Mild (n =45, 43)	13.3 (5.1 to 26.8)	0 (0.0 to 8.2)		
Swelling: Moderate (n =45, 43)	13.3 (5.1 to 26.8)	4.7 (0.6 to 15.8)		
Swelling: Severe (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		
Pain at injection site: Any (n =45, 43)	93.3 (81.7 to 98.6)	60.5 (44.4 to 75.0)		
Pain at injection site: Mild (n =45, 43)	44.4 (29.6 to 60.0)	30.2 (17.2 to 46.1)		
Pain at injection site: Moderate (n =45, 43)	35.6 (21.9 to 51.2)	27.9 (15.3 to 43.7)		
Pain at injection site: Severe (n =45, 43)	13.3 (5.1 to 26.8)	2.3 (0.1 to 12.3)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Systemic Events Within 7 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Systemic Events Within 7 Days After Vaccination 1 ^[9] ^[10]
-----------------	---

End point description:

Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever (≥ 38.0 degree [deg] Celsius [C]) and classified as 38.0-38.4, 38.5-38.9, 39.0-40.0 and >40.0 deg C. Headache, fatigue, chills, muscle pain and joint pain graded as mild (didn't interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (>2 times in 24 hrs) and severe (required intravenous [IV] hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (≥ 6 in 24 hrs). Vaccination 1 safety set was used. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. "Number of Subjects Analyzed"= number of subjects in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 1

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)				
Fever: More than or equal (\geq) 38.0 deg C	3.8 (0.5 to 13.0)	2.0 (0.0 to 10.4)		
Fever: 38.0 to 38.4 deg C	1.9 (0.0 to 10.1)	0 (0.0 to 7.0)		
Fever: More than ($>$) 38.4 to 38.9 deg C	0 (0.0 to 6.7)	2.0 (0.0 to 10.4)		
Fever: $>$ 38.9 to 40.0 deg C	1.9 (0.0 to 10.1)	0 (0.0 to 7.0)		
Fever: $>$ 40.0 deg C	0 (0.0 to 6.7)	0 (0.0 to 7.0)		
Fatigue: Any	54.7 (40.4 to 68.4)	51.0 (36.6 to 65.2)		
Fatigue: Mild	26.4 (15.3 to 40.3)	39.2 (25.8 to 53.9)		
Fatigue: Moderate	22.6 (12.3 to 36.2)	11.8 (4.4 to 23.9)		
Fatigue: Severe	5.7 (1.2 to 15.7)	0 (0.0 to 7.0)		
Headache: Any	41.5 (28.1 to 55.9)	29.4 (17.5 to 43.8)		
Headache: Mild	18.9 (9.4 to 32.0)	25.5 (14.3 to 39.6)		
Headache: Moderate	18.9 (9.4 to 32.0)	2.0 (0.0 to 10.4)		
Headache: Severe	3.8 (0.5 to 13.0)	2.0 (0.0 to 10.4)		
Chills: Any	15.1 (6.7 to 27.6)	19.6 (9.8 to 33.1)		
Chills: Mild	11.3 (4.3 to 23.0)	17.6 (8.4 to 30.9)		
Chills: Moderate	1.9 (0.0 to 10.1)	2.0 (0.0 to 10.4)		
Chills: Severe	1.9 (0.0 to 10.1)	0 (0.0 to 7.0)		
Muscle Pain: Any	26.4 (15.3 to 40.3)	23.5 (12.8 to 37.5)		
Muscle Pain: Mild	15.1 (6.7 to 27.6)	11.8 (4.4 to 23.9)		
Muscle Pain: Moderate	9.4 (3.1 to 20.7)	9.8 (3.3 to 21.4)		
Muscle Pain: Severe	1.9 (0.0 to 10.1)	2.0 (0.0 to 10.4)		
Joint Pain: Any	22.6 (12.3 to 36.2)	19.6 (9.8 to 33.1)		
Joint Pain: Mild	9.4 (3.1 to 20.7)	11.8 (4.4 to 23.9)		
Joint Pain: Moderate	9.4 (3.1 to 20.7)	5.9 (1.2 to 16.2)		
Joint Pain: Severe	3.8 (0.5 to 13.0)	2.0 (0.0 to 10.4)		
Vomiting: Any	1.9 (0.0 to 10.1)	2.0 (0.0 to 10.4)		
Vomiting: Mild	1.9 (0.0 to 10.1)	2.0 (0.0 to 10.4)		

Vomiting: Moderate	0 (0.0 to 6.7)	0 (0.0 to 7.0)		
Vomiting: Severe	0 (0.0 to 6.7)	0 (0.0 to 7.0)		
Diarrhea: Any	9.4 (3.1 to 20.7)	11.8 (4.4 to 23.9)		
Diarrhea: Mild	9.4 (3.1 to 20.7)	5.9 (1.2 to 16.2)		
Diarrhea: Moderate	0 (0.0 to 6.7)	5.9 (1.2 to 16.2)		
Diarrhea: Severe	0 (0.0 to 6.7)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Systemic Events Within 7 Days After Vaccination 2

End point title	Percentage of Subjects Reporting Systemic Events Within 7 Days After Vaccination 2 ^{[11][12]}
-----------------	--

End point description:

Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, diarrhea. Fever (≥ 38.0 deg C) and classified as 38.0-38.4, 38.5-38.9, 39.0-40.0 and >40.0 deg C. Headache, fatigue, chills, muscle pain and joint pain graded as mild (didn't interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (>2 times in 24 hrs) and severe (required IV hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (≥ 6 in 24 hrs). Vaccination 2 safety set was used. Historical data of the age- and sex-matched healthy subjects relevant for endpoint used for control arm. "Number of Subjects Analyzed"= subjects in the given safety set. All subjects in given safety set are not contributing to data for each specified rows but were evaluable for endpoint. "n" = subjects analysed for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 2

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)				
Fever: ≥ 38.0 deg C (n =45, 43)	2.2 (0.1 to 11.8)	2.3 (0.1 to 12.3)		
Fever: 38.0 to 38.4 deg C (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Fever: >38.4 to 38.9 deg C (n =45, 43)	0 (0.0 to 7.9)	2.3 (0.1 to 12.3)		
Fever: >38.9 to 40.0 deg C (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		

Fever: >40.0 deg C (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		
Fatigue: Any (n =45, 43)	53.3 (37.9 to 68.3)	41.9 (27.0 to 57.9)		
Fatigue: Mild (n =45, 43)	24.4 (12.9 to 39.5)	23.3 (11.8 to 38.6)		
Fatigue: Moderate (n =45, 43)	24.4 (12.9 to 39.5)	14.0 (5.3 to 27.9)		
Fatigue: Severe (n =45, 43)	4.4 (0.5 to 15.1)	4.7 (0.6 to 15.8)		
Headache: Any (n =45, 43)	35.6 (21.9 to 51.2)	30.2 (17.2 to 46.1)		
Headache: Mild (n =45, 43)	6.7 (1.4 to 18.3)	23.3 (11.8 to 38.6)		
Headache: Moderate (n =45, 43)	22.2 (11.2 to 37.1)	7.0 (1.5 to 19.1)		
Headache: Severe (n =45, 43)	6.7 (1.4 to 18.3)	0 (0.0 to 8.2)		
Chills: Any (n =45, 43)	8.9 (2.5 to 21.2)	14.0 (5.3 to 27.9)		
Chills: Mild (n =45, 43)	4.4 (0.5 to 15.1)	11.6 (3.9 to 25.1)		
Chills: Moderate (n =45, 43)	2.2 (0.1 to 11.8)	2.3 (0.1 to 12.3)		
Chills: Severe (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Muscle Pain: Any (n =45, 43)	13.3 (5.1 to 26.8)	11.6 (3.9 to 25.1)		
Muscle Pain: Mild (n =45, 43)	4.4 (0.5 to 15.1)	7.0 (1.5 to 19.1)		
Muscle Pain: Moderate (n =45, 43)	8.9 (2.5 to 21.2)	2.3 (0.1 to 12.3)		
Muscle Pain: Severe (n =45, 43)	0 (0.0 to 7.9)	2.3 (0.1 to 12.3)		
Joint Pain: Any (n =45, 43)	20.0 (9.6 to 34.6)	16.3 (6.8 to 30.7)		
Joint Pain: Mild (n =45, 43)	6.7 (1.4 to 18.3)	14.0 (5.3 to 27.9)		
Joint Pain: Moderate (n =45, 43)	11.1 (3.7 to 24.1)	0 (0.0 to 8.2)		
Joint Pain: Severe (n =45, 43)	2.2 (0.1 to 11.8)	2.3 (0.1 to 12.3)		
Vomiting: Any (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Vomiting: Mild (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Vomiting: Moderate (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		
Vomiting: Severe (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		
Diarrhea: Any (n =45, 43)	8.9 (2.5 to 21.2)	4.7 (0.6 to 15.8)		
Diarrhea: Mild (n =45, 43)	6.7 (1.4 to 18.3)	4.7 (0.6 to 15.8)		
Diarrhea: Moderate (n =45, 43)	2.2 (0.1 to 11.8)	0 (0.0 to 8.2)		
Diarrhea: Severe (n =45, 43)	0 (0.0 to 7.9)	0 (0.0 to 8.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1 ^[13] ^[14]
-----------------	--

End point description:

Vaccination 1 safety set included all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 1

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	34.0 (21.5 to 48.3)	9.8 (3.3 to 21.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2

End point title	Percentage of Subjects Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2 ^[15] ^[16]
-----------------	--

End point description:

Vaccination 2 safety set included all subjects who received the second dose of study intervention at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects who were analysed for this endpoint and contributed to the data.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after Vaccination 2

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	45	43		
Units: Percentage of subjects				
number (confidence interval 95%)	28.9 (16.4 to 44.3)	7.0 (1.5 to 19.1)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Adverse Events (AEs) During 30 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Adverse Events (AEs) During 30 Days After Vaccination 1 ^[17] ^[18]
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events. Vaccination 1 safety set included all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after Vaccination 1

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	26.4 (15.3 to 40.3)	9.8 (3.3 to 21.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting AEs During 30 Days After Vaccination 2

End point title	Percentage of Subjects Reporting AEs During 30 Days After Vaccination 2 ^{[19][20]}
-----------------	---

End point description:

An AE was any untoward medical occurrence in a subject or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events. Vaccination 2 safety set included all subjects who received the second dose of study intervention at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after Vaccination 2

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)	12.8 (4.8 to 25.7)	12.8 (4.8 to 25.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting AEs During the Vaccination Phase

End point title	Percentage of Subjects Reporting AEs During the Vaccination Phase ^{[21][22]}
-----------------	---

End point description:

An AE was any untoward medical occurrence in a subject or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Vaccination Phase: From Vaccination 1 through one Month after Vaccination 2 (approximately 7 Months)

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	60.4 (46.0 to 73.5)	41.2 (27.6 to 55.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting AEs During 30 Days After any Vaccination

End point title	Percentage of Subjects Reporting AEs During 30 Days After any Vaccination ^{[23][24]}
-----------------	---

End point description:

An AE was any untoward medical occurrence in a subject or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after any Vaccination

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	34.0 (21.5 to 48.3)	17.6 (8.4 to 30.9)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting SAEs During 30 Days After Vaccination 2

End point title	Percentage of Subjects Reporting SAEs During 30 Days After Vaccination 2 ^[25] ^[26]
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event. Vaccination 2 safety set included all subjects who received the second dose of study intervention at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after Vaccination 2

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)	0 (0.0 to 7.5)	0 (0.0 to 7.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting SAEs During 30 Days After any Vaccination

End point title	Percentage of Subjects Reporting SAEs During 30 Days After any Vaccination ^[27] ^[28]
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after any Vaccination

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	9.4 (3.1 to 20.7)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting SAEs During the Vaccination Phase

End point title	Percentage of Subjects Reporting SAEs During the Vaccination Phase ^{[29][30]}
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all

the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	17.0 (8.1 to 29.8)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1 ^[31] ^[32]
-----------------	---

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event. Vaccination 1 safety set included all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after Vaccination 1

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	9.4 (3.1 to 20.7)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting SAEs During the Entire Study

End point title	Percentage of Subjects Reporting SAEs During the Entire
-----------------	---

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	18.9 (9.4 to 32.0)	2.0 (0.0 to 10.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting MAEs During 30 Days After Vaccination 2

End point title	Percentage of Subjects Reporting MAEs During 30 Days After Vaccination 2 ^[35] [36]
-----------------	---

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Vaccination 2 safety set included all subjects who received the second dose of study intervention

at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
End point timeframe:	
30 Days after Vaccination 2	

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)	12.8 (4.8 to 25.7)	4.3 (0.5 to 14.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting SAEs During the Follow-up Phase

End point title	Percentage of Subjects Reporting SAEs During the Follow-up Phase ^{[37][38]}
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event. Follow-up safety set included all subjects who received at least 1 dose of study intervention and for whom safety information was available from after Visit 4 up to and including Visit 5 Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	44	48		
Units: Percentage of subjects				
number (confidence interval 95%)	4.5 (0.6 to 15.5)	2.1 (0.1 to 11.1)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1

End point title	Percentage of Subjects Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1 ^[39] ^[40]
-----------------	---

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Vaccination 1 safety set included all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after Vaccination 1

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	20.8 (10.8 to 34.1)	5.9 (1.2 to 16.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting MAEs During the Follow-up Phase

End point title	Percentage of Subjects Reporting MAEs During the Follow-up
-----------------	--

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Follow-up safety set included all subjects who received at least 1 dose of study intervention and for whom safety information was available from after Visit 4 up to and including Visit 5. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type

Primary

End point timeframe:

Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	44	48		
Units: Percentage of subjects				
number (confidence interval 95%)	15.9 (6.6 to 30.1)	10.4 (3.5 to 22.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting MAEs During the Vaccination Phase

End point title

Percentage of Subjects Reporting MAEs During the Vaccination Phase^[43][44]

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type

Primary

End point timeframe:

Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	54.7 (40.4 to 68.4)	29.4 (17.5 to 43.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting MAEs During 30 days After any Vaccination

End point title	Percentage of Subjects Reporting MAEs During 30 days After any Vaccination ^[45] ^[46]
-----------------	--

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

30 Days after any Vaccination

Notes:

[45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	30.2 (18.3 to 44.3)	9.8 (3.3 to 21.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Immediate AEs After Vaccination 1

End point title	Percentage of Subjects Reporting Immediate AEs After Vaccination 1 ^[47] ^[48]
-----------------	--

End point description:

Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration. Vaccination 1 safety set included all subjects who received the first dose of study intervention at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Minutes post Vaccination 1

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	0 (0.0 to 6.7)	2.0 (0.0 to 10.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Immediate AEs After Vaccination 2

End point title	Percentage of Subjects Reporting Immediate AEs After Vaccination 2 ^[49] [50]
-----------------	---

End point description:

Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration. Vaccination 2 safety set included all subjects who received the second dose of study intervention at Visit 3 and for whom safety information was available from Visit 3 up to and including Visit 4. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

30 Minutes post Vaccination 2

Notes:

[49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Percentage of subjects				
number (confidence interval 95%)	0 (0.0 to 7.5)	0 (0.0 to 7.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting MAEs During the Entire Study

End point title	Percentage of Subjects Reporting MAEs During the Entire
-----------------	---

End point description:

Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	60.4 (46.0 to 73.5)	31.4 (19.1 to 45.9)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase

End point title	Percentage of Subjects With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase ^{[53][54]}
-----------------	--

End point description:

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

Notes:

[53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	1.9 (0.0 to 10.1)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With NDCMC During the Follow-up Phase

End point title	Percentage of Subjects With NDCMC During the Follow-up Phase ^{[55][56]}
-----------------	--

End point description:

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. Follow-up safety set included all subjects who received at least 1 dose of study intervention and for whom safety information was available from after Visit 4 up to and including Visit 5. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects present in the given safety set.

End point type	Primary
----------------	---------

End point timeframe:

Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	44	48		
Units: Percentage of subjects				
number (confidence interval 95%)	0 (0.0 to 8.0)	0 (0.0 to 7.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects With NDCMC During the Entire Study

End point title	Percentage of Subjects With NDCMC During the Entire
-----------------	---

End point description:

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm.

End point type	Primary
----------------	---------

End point timeframe:

Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	51		
Units: Percentage of subjects				
number (confidence interval 95%)	1.9 (0.0 to 10.1)	0 (0.0 to 7.0)		

Statistical analyses

No statistical analyses for this end point

Primary: Number of Days Subjects Missed School or Work Because of AEs During the Vaccination Phase

End point title	Number of Days Subjects Missed School or Work Because of AEs During the Vaccination Phase ^{[59][60]}
-----------------	---

End point description:

An AE is any untoward medical occurrence in a subject or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Safety set included all enrolled subjects who received at least 1 dose of the study intervention and have safety data reported after vaccination. Historical data of the age- and sex-matched healthy subjects relevant for this endpoint used for control arm. Here, "Number of Subjects Analyzed" signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

Notes:

[59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned for this endpoint.

[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Subject analysis set has been created to report data for control arm.

End point values	Trumenba	Trumenba: From B1971057, Control Arm		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	32	21		
Units: Days				
arithmetic mean (standard deviation)	12.7 (± 7.6)	2.5 (± 2.3)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Local reactions, systemic events within 7 days of each vaccination; SAEs and Non-SAEs: From Day 1 of vaccination up to 6 months after last study vaccination (approximately 12 months)

Adverse event reporting additional description:

Same event may appear as both AE and SAE but are distinct events. An event may be categorized as serious in 1 subject and non-serious in another, or a subject may have experienced both SAE and non-SAE. For study B1971057 MedDRA version 25.1 was used and for study B1971060 MedDRA version 26.0 was used.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.0

Reporting groups

Reporting group title	Trumenba: From B1971057, Control Arm
-----------------------	--------------------------------------

Reporting group description:

Age- and sex-matched healthy subjects from group 2 or 4 (Trumenba groups) from Phase 3 study B1971057 Stage 1(NCT ID: NCT04893811/EudraCT Number: 2016-004421-17) were randomly selected and included in this group. This arm served as a control arm for the study.

Reporting group title	Trumenba
-----------------------	----------

Reporting group description:

Immunocompromised subjects ≥ 10 years of age with asplenia (anatomic or functional) or complement deficiency, received Trumenba 0.5 mL, IM on Day 1 of Visit 1 (Month 0) and Visit 3 (Month 6).

Serious adverse events	Trumenba: From B1971057, Control Arm	Trumenba	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 51 (1.96%)	10 / 53 (18.87%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Wrist fracture			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			

Acute myocardial infarction			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Blood and lymphatic system disorders			
Sickle cell anaemia with crisis			
subjects affected / exposed	0 / 51 (0.00%)	4 / 53 (7.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal disorders			
Pancreatitis chronic			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Trumenba: From B1971057, Control Arm	Trumenba	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	49 / 51 (96.08%)	51 / 53 (96.23%)	
Vascular disorders			
Secondary hypertension			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 51 (13.73%)	17 / 53 (32.08%)	
occurrences (all)	8	24	
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 51 (3.92%)	2 / 53 (3.77%)	
occurrences (all)	2	3	
Injection site pain (PAIN AT INJECTION SITE)			
alternative assessment type: Systematic			
subjects affected / exposed	45 / 51 (88.24%)	48 / 53 (90.57%)	
occurrences (all)	67	88	
Chills (CHILLS)			
alternative assessment type: Systematic			
subjects affected / exposed	11 / 51 (21.57%)	11 / 53 (20.75%)	
occurrences (all)	16	12	
Fatigue (FATIGUE)			
alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	27 / 51 (52.94%) 44	31 / 53 (58.49%) 53	
Fatigue subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 53 (1.89%) 1	
Injection site pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 53 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Reproductive system and breast disorders Ovarian cyst subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Vocal cord polyp subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Pleurisy subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Investigations SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	2 / 53 (3.77%) 2	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 2	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	

Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Fall			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	
Incisional hernia			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	
Limb injury			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Skin laceration			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Soft tissue injury			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	
Thermal burn			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	
occurrences (all)	0	1	
Nervous system disorders			
Syncope			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Hypoaesthesia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Headache			
subjects affected / exposed	2 / 51 (3.92%)	0 / 53 (0.00%)	
occurrences (all)	3	0	
Dizziness			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Headache (HEADACHE)			

alternative assessment type: Systematic subjects affected / exposed occurrences (all)	21 / 51 (41.18%) 28	25 / 53 (47.17%) 38	
Blood and lymphatic system disorders Sickle cell anaemia with crisis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 2	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Eye disorders Periorbital swelling subjects affected / exposed occurrences (all) Eye haemorrhage subjects affected / exposed occurrences (all) Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0 0 / 51 (0.00%) 0 1 / 51 (1.96%) 1	1 / 53 (1.89%) 1 1 / 53 (1.89%) 1 0 / 53 (0.00%) 0	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Abdominal pain upper subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Diarrhoea (DIARRHEA) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Vomiting (VOMITING) alternative assessment type:	2 / 51 (3.92%) 2 0 / 51 (0.00%) 0 0 / 51 (0.00%) 0 7 / 51 (13.73%) 8	0 / 53 (0.00%) 0 1 / 53 (1.89%) 1 1 / 53 (1.89%) 1 8 / 53 (15.09%) 9	

Systematic subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	2 / 53 (3.77%) 2	
Vomiting subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Skin and subcutaneous tissue disorders Erythema (REDNESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	6 / 51 (11.76%) 9	14 / 53 (26.42%) 19	
Acne subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 53 (1.89%) 1	
Drug eruption subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Night sweats subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Rash subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Urticaria subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Renal and urinary disorders Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia (JOINT PAIN) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	13 / 51 (25.49%) 17	14 / 53 (26.42%) 21	
Myalgia (MUSCLE PAIN)			

alternative assessment type: Systematic			
subjects affected / exposed	14 / 51 (27.45%)	16 / 53 (30.19%)	
occurrences (all)	17	20	
Back pain			
subjects affected / exposed	0 / 51 (0.00%)	3 / 53 (5.66%)	
occurrences (all)	0	3	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	1 / 51 (1.96%)	1 / 53 (1.89%)	
occurrences (all)	1	1	
Soft tissue swelling			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	2 / 51 (3.92%)	0 / 53 (0.00%)	
occurrences (all)	2	0	
COVID-19			
subjects affected / exposed	0 / 51 (0.00%)	5 / 53 (9.43%)	
occurrences (all)	0	5	
Urethritis mycoplasmal			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Tonsillitis streptococcal			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	4 / 51 (7.84%)	2 / 53 (3.77%)	
occurrences (all)	5	2	
Tracheitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	
occurrences (all)	1	0	
Urinary tract infection			

subjects affected / exposed	1 / 51 (1.96%)	1 / 53 (1.89%)
occurrences (all)	1	1
Chronic sinusitis		
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)
occurrences (all)	0	1
Conjunctivitis		
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)
occurrences (all)	1	0
Furuncle		
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)
occurrences (all)	1	0
Hordeolum		
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	0 / 51 (0.00%)	5 / 53 (9.43%)
occurrences (all)	0	5
Nasopharyngitis		
subjects affected / exposed	1 / 51 (1.96%)	1 / 53 (1.89%)
occurrences (all)	1	1
Oral herpes		
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)
occurrences (all)	0	1
Otitis media		
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)
occurrences (all)	1	0
Otitis media bacterial		
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)
occurrences (all)	1	0
Pharyngitis		
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)
occurrences (all)	0	1
Pharyngitis streptococcal		
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)
occurrences (all)	0	1
Respiratory tract infection		

subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Sinusitis subjects affected / exposed occurrences (all)	4 / 51 (7.84%) 4	0 / 53 (0.00%) 0	
Tonsillitis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	4 / 53 (7.55%) 4	
Urethritis subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Viral pharyngitis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	2 / 53 (3.77%) 2	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 53 (0.00%) 0	
Metabolism and nutrition disorders Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 53 (1.89%) 1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported